Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$63.71 - $70.74 $4,459 - $4,951
-70 Reduced 0.45%
15,515 $992,000
Q1 2023

May 05, 2023

SELL
$65.71 - $74.53 $4,928 - $5,589
-75 Reduced 0.48%
15,585 $1.08 Million
Q4 2022

Jan 23, 2023

BUY
$68.48 - $81.09 $647,820 - $767,111
9,460 Added 152.58%
15,660 $0
Q3 2022

Oct 18, 2022

BUY
$0.13 - $76.84 $468 - $276,624
3,600 Added 138.46%
6,200 $440,000
Q2 2022

Aug 03, 2022

SELL
$72.62 - $79.98 $290,480 - $319,920
-4,000 Reduced 60.61%
2,600 $200,000
Q1 2022

May 13, 2022

SELL
$61.48 - $73.72 $9,222 - $11,058
-150 Reduced 2.22%
6,600 $483,000
Q4 2020

Jan 19, 2021

BUY
$57.74 - $65.43 $9,815 - $11,123
170 Added 2.58%
6,750 $419,000
Q4 2020

Jan 14, 2021

SELL
$57.74 - $65.43 $9,815 - $11,123
-170 Reduced 2.52%
6,580 $342,000
Q3 2020

Nov 03, 2020

SELL
$57.43 - $63.64 $25,843 - $28,638
-450 Reduced 6.25%
6,750 $407,000
Q2 2020

Aug 13, 2020

BUY
$54.82 - $64.09 $1,096 - $1,281
20 Added 0.28%
7,200 $424,000
Q1 2020

May 08, 2020

SELL
$46.4 - $67.43 $38,280 - $55,629
-825 Reduced 10.31%
7,180 $400,000
Q4 2019

Jan 15, 2020

BUY
$49.21 - $64.19 $9,842 - $12,838
200 Added 2.56%
8,005 $514,000
Q3 2019

Nov 05, 2019

BUY
$42.77 - $50.71 $65,224 - $77,332
1,525 Added 24.28%
7,805 $395,000
Q2 2019

Jul 12, 2019

SELL
$44.62 - $49.34 $8,924 - $9,868
-200 Reduced 3.09%
6,280 $284,000
Q1 2019

May 08, 2019

SELL
$45.12 - $53.8 $4,512 - $5,380
-100 Reduced 1.52%
6,480 $309,000
Q2 2018

Jul 16, 2018

SELL
$50.53 - $62.98 $3,031 - $3,778
-60 Reduced 0.9%
6,580 $364,000
Q3 2017

Nov 14, 2017

SELL
$55.23 - $63.74 $2,761 - $3,187
-50 Reduced 0.75%
6,640 $423,000
Q3 2017

Nov 01, 2017

BUY
$55.23 - $63.74 $369,488 - $426,420
6,690
6,690 $372,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Community Bank Of Raymore Portfolio

Follow Community Bank Of Raymore and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Community Bank Of Raymore, based on Form 13F filings with the SEC.

News

Stay updated on Community Bank Of Raymore with notifications on news.